Skandinaviska Enskilda Banken AB publ Takes $853,000 Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Skandinaviska Enskilda Banken AB publ purchased a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the 2nd quarter, HoldingsChannel reports. The fund purchased 25,217 shares of the biotechnology company’s stock, valued at approximately $853,000.

Several other hedge funds also recently modified their holdings of ARCT. Quantbot Technologies LP acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at about $53,000. US Bancorp DE increased its stake in shares of Arcturus Therapeutics by 276.6% in the first quarter. US Bancorp DE now owns 1,770 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 1,300 shares during the period. E Fund Management Co. Ltd. acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at about $116,000. Victory Capital Management Inc. acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at about $204,000. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Arcturus Therapeutics by 88.2% in the first quarter. BNP Paribas Arbitrage SA now owns 5,093 shares of the biotechnology company’s stock valued at $210,000 after buying an additional 2,387 shares during the period. 77.64% of the stock is owned by institutional investors.

Shares of NASDAQ:ARCT opened at $51.81 on Wednesday. The business’s 50 day simple moving average is $46.22 and its two-hundred day simple moving average is $39.64. The firm has a market cap of $1.36 billion, a P/E ratio of -8.11 and a beta of 2.91. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.81 and a current ratio of 8.81. Arcturus Therapeutics Holdings Inc. has a 52-week low of $24.87 and a 52-week high of $129.71.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Sunday, August 8th. The biotechnology company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.99) by ($0.08). Arcturus Therapeutics had a negative return on equity of 48.39% and a negative net margin of 1,874.18%. On average, equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -6.06 earnings per share for the current fiscal year.

In other Arcturus Therapeutics news, Director Ultragenyx Pharmaceutical Inc. sold 725,000 shares of the firm’s stock in a transaction on Tuesday, August 10th. The stock was sold at an average price of $55.44, for a total value of $40,194,000.00. Following the completion of the sale, the director now directly owns 1,475,000 shares of the company’s stock, valued at $81,774,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Pad Chivukula sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 3rd. The stock was sold at an average price of $40.07, for a total value of $400,700.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 745,000 shares of company stock worth $41,153,300. Corporate insiders own 12.20% of the company’s stock.

ARCT has been the subject of several recent research reports. Cantor Fitzgerald increased their price target on Arcturus Therapeutics from $71.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, August 10th. The Goldman Sachs Group lowered Arcturus Therapeutics from a “neutral” rating to a “sell” rating and set a $29.00 target price on the stock. in a research report on Tuesday, August 10th. Barclays lowered Arcturus Therapeutics from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $33.00 to $25.00 in a research report on Monday, June 21st. Zacks Investment Research upgraded Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 10th. Finally, Citigroup cut their target price on Arcturus Therapeutics from $118.00 to $114.00 and set a “buy” rating on the stock in a research report on Wednesday, August 25th. Six investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $69.33.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings, Inc is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Read More: What is the definition of market timing?

Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT).

Institutional Ownership by Quarter for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.